1. Home
  2. ACET vs PARK Comparison

ACET vs PARK Comparison

Compare ACET & PARK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

SELL

Current Price

$6.37

Market Cap

83.3M

Sector

Health Care

ML Signal

SELL

Logo Park Dental Partners Inc.

PARK

Park Dental Partners Inc.

N/A

Current Price

$21.39

Market Cap

94.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ACET
PARK
Founded
1947
1972
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Misc Health and Biotechnology Services
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.3M
94.5M
IPO Year
2017
2025

Fundamental Metrics

Financial Performance
Metric
ACET
PARK
Price
$6.37
$21.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
2
Target Price
★ $34.83
$28.50
AVG Volume (30 Days)
★ 272.2K
36.0K
Earning Date
11-04-2026
11-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ 0.16
Revenue
N/A
N/A
Revenue This Year
N/A
$5.58
Revenue Next Year
N/A
$15.70
P/E Ratio
★ N/A
$131.81
Revenue Growth
N/A
N/A
52 Week Low
$0.46
$12.29
52 Week High
$9.97
$26.79

Technical Indicators

Market Signals
Indicator
ACET
PARK
Relative Strength Index (RSI) 34.28 56.71
Support Level N/A $19.23
Resistance Level $8.85 $22.65
Average True Range (ATR) 0.69 0.93
MACD -0.28 0.09
Stochastic Oscillator 3.45 96.27

Price Performance

Historical Comparison
ACET
PARK

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

About PARK Park Dental Partners Inc.

Park Dental Partners Inc is a dental resource organization (DRO) operating through its subsidiary. It Provides comprehensive business support services including clinical team members, administrative personnel, facilities and equipment to its affiliated general and multi-specialty dental practices throughout Minnesota and Wisconsin. Its network of affiliated dental practices provides both general and specialty dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics, under long-term agreements with initial terms of 30-years, with automatic 5-year renewals.

Share on Social Networks: